Related Experiment Video
Updated: Aug 10, 2026
04:22
Disposable Dosators for Pulmonary Insufflation of Therapeutic Agents to Small Animals
Published on: March 30, 2017
Are outcomes the same with all dry powder inhalers?
1Department of General Practice, University of Aberdeen, UK.
International Journal of Clinical Practice. Supplement
|November 11, 2005
Summary
Real-world asthma care shows inhaler choice matters. Patients using DISKHALER needed less short-acting beta(2)-agonist than those using ROTAHALER, indicating better asthma control with certain devices.
Area of Science:
- Pulmonary Medicine
- Pharmacology
- Real-World Evidence
Background:
- Clinical effectiveness of inhaler devices in asthma is debated.
- Systematic reviews of randomized controlled trials (RCTs) suggest no significant difference between dry powder inhalers (DPIs) and metered-dose inhalers (MDIs).
- Real-world factors like patient behavior are critical for device efficacy.
Purpose of the Study:
- To investigate the impact of different dry powder inhaler devices on asthma outcomes in a real-world setting.
- To compare the use of short-acting beta(2)-agonist (SABA) among patients using beclometasone dipropionate via DISKHALER versus ROTAHALER.
- To assess if inhaler device choice influences asthma control in routine clinical practice.
Main Methods:
- Utilized the IMS Mediplus database for observational, real-world data.
- Compared outcomes for patients receiving beclometasone dipropionate maintenance therapy.
- Analyzed SABA usage as a proxy for asthma control in patients using DISKHALER versus ROTAHALER.
Main Results:
- Patients using the DISKHALER dry powder inhaler required significantly less SABA compared to those using the ROTAHALER.
- This finding suggests a difference in asthma control levels between the two DPI devices, even with the same active medication.
- Real-world data indicates variability in outcomes among different DPIs.
Conclusions:
- Inhaler device selection significantly impacts asthma outcomes in real-world primary care.
- Different dry powder inhalers may lead to varying levels of asthma control.
- Further research is warranted to explore the influence of inhaler device choice and switching devices on patient outcomes.
Related Concept Videos
01:16Bioequivalence: Overview
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
01:30Asthma-IV: Diagnostic and Management
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
01:23Inhaled Medications
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
01:22Drug Delivery: Miscellaneous Routes
Drug delivery methods like oral inhalation, nasal sprays, transdermal patches, eye drops, intravitreal injection, and rectal administration provide localized effects with reduced toxicity.
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs through the...
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs through the...
01:26Pharmaceutical Equivalents
As defined by regulatory standards, pharmaceutical equivalents require generic drug products to have identical dosage forms and chemically identical active pharmaceutical ingredients (APIs). They must adhere to compendial or applicable standards for potency, content uniformity, disintegration times, and dissolution rates. In the case of modified-release dosage forms, variations in drug content are permissible as long as the delivered amount remains consistent with the innovator drug product.
01:27Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...